ARS Pharmaceuticals Files 8-K

Ticker: SPRY · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1671858

Ars Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyArs Pharmaceuticals, Inc. (SPRY)
Form Type8-K
Filed DateAug 12, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulation-fd, corporate-event

TL;DR

ARS Pharma dropped an 8-K on Friday, check it for Reg FD and other news.

AI Summary

ARS Pharmaceuticals, Inc. filed an 8-K on August 12, 2024, reporting on events that occurred on August 9, 2024. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements and exhibits. The company, formerly known as Silverback Therapeutics, Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing provides updates on significant company events and disclosures, which are crucial for investors to understand the latest developments and potential impacts on the company's stock.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and does not appear to contain immediately concerning financial or operational news.

Key Players & Entities

  • ARS Pharmaceuticals, Inc. (company) — Registrant
  • Silverback Therapeutics, Inc. (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • San Diego, California (location) — Principal executive offices
  • August 9, 2024 (date) — Date of earliest event reported
  • August 12, 2024 (date) — Date of report

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates it is for Regulation FD Disclosure, but the specific details of the disclosure are not provided in the header information.

What are the 'Other Events' being reported?

The filing lists 'Other Events' as an item information category, but the nature of these events is not detailed in the provided text.

When was ARS Pharmaceuticals, Inc. formerly known as Silverback Therapeutics, Inc.?

The date of the name change from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. was April 12, 2016.

What is the principal business address of ARS Pharmaceuticals, Inc.?

The principal executive offices are located at 11682 El Camino Real, Suite 120, San Diego, California, 92130.

What is the SIC code for ARS Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for ARS Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,309 words · 5 min read · ~4 pages · Grade level 14.4 · Accepted 2024-08-12 07:59:39

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This report contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the timeline for neffy 's commercial availability; the Company's plan to file a supplemental regulatory application for a neffy 1 mg product for children 15 kg to <30 kg; the timeline for potential regulatory approval and commercialization of EUR neffy in Europe; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "expected," "will," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the ability to maintain regulatory approval for neffy ; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from neffy ; neffy may fail to achieve the degree of market acceptance by allergists, pediatricians and other physicians, patients, caregivers, third-party payors and others in the medical community necessary for commercial success; if we are unable to fully develop our sales, marketing and distribution capability, we may not be successful in commercializing neffy in the United States; the labeling for neffy in any future indication or patient population; the scope, progress and expansion of developing and commercializing neffy ; the potential for payors to delay, limit or deny coverage for neffy ; the size and g

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Company Presentation, dated August 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARS PHARMACEUTICALS, INC. Date: August 12, 2024 By: /s/ Richard Lowenthal Richard Lowenthal, M.S., MBA President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.